Patients were divided into two groups: (a) 348 patients with bladder cancer from the IMvigor 210 trial phase 2 who were treated with the PD-L1 inhibitor “Atezolizumab,“ and (b) 71 patients with melanoma who were treated with anti-PD-1, anti-cytotoxic T-lymphocyte–associated protein 4 (CTLA4), and cytokine tumor vaccine. The gene discussed is CTLA4; the disease is neoplasm.